{"id":799883,"date":"2025-01-13T07:53:20","date_gmt":"2025-01-13T12:53:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/"},"modified":"2025-01-13T07:53:20","modified_gmt":"2025-01-13T12:53:20","slug":"silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"<h2>\nSilexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>Cayman Islands, January 13, 2025 &#8212; Silexion Therapeutics Corp. (NASDAQ: SLXN) (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. <\/p>\n<p>The 2025 ASCO\u00a0Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients.<\/p>\n<p>Silexion\u2019s abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025. Following the presentation, the poster will be available on Silexion Therapeutics\u2019 website under the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_EmHtHtRj2st-Hlds6Z2jQfvVhjuBKKNKVuojjZIYqKzMktdr0m_ndZAWmjmS0fc-ocCipa1zWcnsUxpzd0n6LVurcAPYz4lH__ynioTkyM=\" rel=\"nofollow\" target=\"_blank\">Our Science<\/a>\u201d section.<\/p>\n<p>\n        \n      <\/p>\n<p>\n        <u>Presentation Details<\/u>\n      <\/p>\n<p>\n        <b>Title:<\/b> SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation<br \/><b>Presenter:<\/b> Mitchell Shirvan, Ph.D.<br \/><b>Session:<\/b> Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract<br \/><b>Abstract Number:<\/b> 745<br \/><b>Session Date &amp; Time:<\/b> January 24, 2025, 11:30 AM-1:00 PM PST<\/p>\n<p>\n        \n      <\/p>\n<p>\n        <b>About Silexion Therapeutics<\/b>\n      <\/p>\n<p>Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company&#8217;s first-generation product, LODER\u2122, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t3LmD-nvMqr539nozqgBoZ29AFkBLIzbDHcRBtgJcN4rj4Vuo5TmWzxMlP-K5kSWkAcWl5TzIijWgJ3HMPcMdcVrFZ7l4TJDh5ux8Fm_IyQiM08zSzHMW_shhWrAzzcDr4uzaWplylZloJ_RNiCbGSLJkhvyueaxHl7z8rnH1ffKeSHYe6XbU8Nyugn0QSnS_RLBbutYRefeUXkM6JRRNEogs76Q5QhU3Ia5bc2HQDh86Df2cdhB2tMtGHU2nnAHcvc9dq-ySEbPzTMEWxopMw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/silexion.com<\/a><\/p>\n<p>\n        <b><br \/>\n          <br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Company Contact:<\/b>\n      <\/p>\n<p>Silexion Therapeutics Corp<br \/> Ms. Mirit Horenshtein Hadar, CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XZfRz9HbAo3WTQoN4-tHJ8e_vD1vYm0QiP_yNic4LJ7rv4qS2T_VPeXGxueGYgzrAIz41CeK73DgaEXGmfZx_BWX9WR3eWpIp3ga6tc4zg4=\" rel=\"nofollow\" target=\"_blank\"> mirit@silexion.com<\/a><\/p>\n<p>\n        <strong>Capital Markets &amp; IR Contact<\/strong>\n      <\/p>\n<p>ARX | Capital Markets Advisors<br \/> North American Equities Desk<br \/> silexion@arxadvisory.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NjFhYWZlZjEtMTIxZS00ZTYxLTg2NjAtYWNjYjJhN2I1NTY3LTEzMDgyMjI=\/tiny\/Silexion-Therapeutics-Corp.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Cayman Islands, January 13, 2025 &#8212; Silexion Therapeutics Corp. (NASDAQ: SLXN) (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. The 2025 ASCO\u00a0Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. Silexion\u2019s abstract will be published on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799883","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Cayman Islands, January 13, 2025 &#8212; Silexion Therapeutics Corp. (NASDAQ: SLXN) (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. The 2025 ASCO\u00a0Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. Silexion\u2019s abstract will be published on the &hellip; Continue reading &quot;Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T12:53:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium\",\"datePublished\":\"2025-01-13T12:53:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/\",\"name\":\"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\",\"datePublished\":\"2025-01-13T12:53:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","og_description":"Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Cayman Islands, January 13, 2025 &#8212; Silexion Therapeutics Corp. (NASDAQ: SLXN) (\u201cSilexion\u201d or the \u201cCompany\u201d), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California. The 2025 ASCO\u00a0Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients. Silexion\u2019s abstract will be published on the &hellip; Continue reading \"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-13T12:53:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium","datePublished":"2025-01-13T12:53:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/","name":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==","datePublished":"2025-01-13T12:53:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA0MjQxMCM0MDIwNDMwODkjMjI5NjY3Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silexion-therapeutics-to-present-sil-204-data-in-kras-driven-pancreatic-cancer-at-the-2025-asco-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799883","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799883"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799883\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799883"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799883"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799883"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}